NGNENeurogene Inc.vs its industry peers
A metric-by-metric comparison of Neurogene Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGNEEsta | $672M#8 | — | 3.1x#5 | — | -100.0%#12 | -20.2%#11 | — | -41.6%#11 | — | — | 89.6%#7 | — |
| DSGN | $765M#1 | — | 3.8x#7 | — | — | -40.7%#13 | — | -34.6%#10 | — | — | 108.8%#6 | — |
| GYRE | $743M#2 | — | 6.9x#10 | 6.4x#5 | 10.2%#7 | -44.8%#14 | 9.9%#4 | 9.2%#5 | 12.0%#3 | 3#3 | -10.5%#12 | 6.1%#1 |
| NVCT | $718M#3 | — | 79.1x#12 | — | — | -39.2%#12 | — | -291.1%#12 | — | — | 253.7%#1 | — |
| COLL | $712M#4 | 17.2x#5 | 2.3x#3 | 0.9x#1 | 23.6%#6 | -8.7%#10 | 23.0%#3 | 20.2%#4 | 62.0%#1 | 4#1 | -37.4%#15 | — |
| MNPR | $700M#5 | — | 5.4x#9 | — | — | 12.0%#8 | — | -10.5%#7 | — | — | 116.2%#4 | — |
| CBIO | $699M#6 | — | 4.3x#8 | 64.4x#9 | — | 306.4%#3 | -1407.5%#10 | 0.1%#6 | — | — | 54.0%#9 | — |
| ZVRA | $692M#7 | 12.5x#4 | 3.2x#6 | 6.5x#6 | 350.9%#2 | 178.9%#4 | -59.1%#5 | 38.2%#1 | — | — | 61.3%#8 | — |
| IRWD | $672M#9 | 5.1x#2 | — | 2.3x#3 | -15.7%#9 | 2629.5%#1 | 33.3%#2 | — | 42.6%#2 | — | 217.6%#3 | — |
| VSTM | $665M#10 | — | 13.3x#11 | 21.5x#8 | 209.1%#4 | -60.3%#15 | -550.3%#9 | -419.1%#13 | — | — | -25.3%#13 | — |
| PHAT | $659M#11 | — | — | 3.8x#4 | 216.9%#3 | 33.8%#7 | -91.4%#6 | — | — | 4#1 | -28.9%#14 | — |
| ALT | $628M#12 | — | 1.3x#2 | 15324.2x#11 | 105.0%#5 | 7.3%#9 | -230461.0%#12 | -18.6%#8 | -21.1%#4 | — | -10.0%#11 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#8 | 76.2%#5 | -111.0%#7 | 22.5%#3 | — | — | 110.5%#5 | — |
| AQST | $605M#13 | — | — | 13.6x#7 | -22.6%#10 | -89.8%#16 | -159.5%#8 | — | — | — | -6.2%#10 | — |
| CRMD | $604M#14 | 3.6x#1 | 1.3x#1 | 1.9x#2 | 617.0%#1 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | -38.7%#16 | — |
| STTK | $599M#15 | — | 2.8x#4 | 599.2x#10 | -82.5%#11 | 35.3%#6 | -5150.8%#11 | -23.1%#9 | — | — | 233.5%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice